Spondylolisthesis, Lumbosacral Region Clinical Trial
Official title:
The Effectiveness and Safety of Traditional Korean Medicine for Symptomatic Lumbar Spinal Spondylolisthesis: a Randomized Controlled International Collaborative Multi-center Trial
| Verified date | January 2021 |
| Source | Mokhuri Oriental Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a clinical trial for evaluating the safety and effectiveness of the Mokhuri intensive treatment program regarding pain and function before and after treatment between a group receiving the Mokhuri intensive treatment program (Chuna, acupuncture, and patient education) for five weeks and another group receiving non-surgical conventional standard treatment (drugs for pain relief, epidural steroid injection treatment, and physical therapy). The trial will be conducted through international cooperation between Mayo Clinic in the United States and Mokhuri Oriental Medicine Hospital in Korea. All subjects in Korea and the US will be selected based on the same inclusion criteria and exclusion criteria. All subjects in the treatment arm will receive the same treatment in Korea and the US. In collaboration and with the support of Mayo Clinic's Department of Integrative Medicine and Health, and to ensure treatment consistency between Korea and the US, an acupuncturist from the USA will travel to Korea and train on-site for one month in Mokhuri hospital. The trial subjects who agree to participate in the clinical trial after providing informed consent will receive the required examinations and tests according to the clinical trial plan. If they are appropriate for this clinical trial and eligible based on the Inclusion and exclusion criteria, they will be randomly assigned to the group that will undergo the focused Mokhuri intensive treatment program and to the group that will receive non-surgical conventional treatment on their second visit. All the subjects in this study will be educated regarding the study procedure and scheduled visits and will participate in the allocated treatments for five weeks. Afterwards, clinical outcomes of both groups will be evaluated after end of the treatments from between a week and five weeks (within +7 days). The clinical trial ends after the follow-up evaluations that will take place 12 weeks, 24 weeks, 48 weeks, and 96 weeks after the end of the treatment evaluation.
| Status | Active, not recruiting |
| Enrollment | 115 |
| Est. completion date | December 31, 2022 |
| Est. primary completion date | December 31, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 19 Years to 78 Years |
| Eligibility | Inclusion Criteria: - Individuals with all the following requirements will be included as appropriate subjects in the clinical trial: 1. Those aged from 19 to 78 years 2. Those with a diagnosis of degenerative lumbar spinal spondylolisthesis and have low back pain, lower limb radiating pain, or leg discomfort when standing or walking with severity of at least 50 in a 0 to 100 VAS for each symptom 3. Those suffering from neurologic claudication or radicular pain at least for one year 4. Those with neurogenic claudication within five minutes when walking on a treadmill at the speed of 1.5 miles per hour 5. Those not receiving epidural injection treatments within the past one month 6. Those who have not undergone lumbar surgery 7. Those who confirmed spondylolisthesis on L-spine AP, lateral & both oblique views 8. Those who weigh 250 lbs (113.398 kg) or less 9. Those who are 2.1 m (6.890 ft) in height or shorter 10. Those agreeing to participate in this clinical trial after receiving a thorough explanation of the purposes and characteristics of the trial and who have also signed the written informed consent form. Exclusion Criteria: - Subjects will be excluded for the following conditions: 1. Those with a history of diseases in the past or in the present that cause ambulatory functional disability 2. Those with knee joint and hip joint disorders that severely limit walking (i.e. moderate or severe osteoarthritis in the knee or hip joints) 3. Those who has been diagnosed as peripheral blood vessel diseases or vascular diseases in the past, shows an ankle-brachial index (ABI) below 0.9 or is diagnosed as peripheral artery disease by Doppler ultrasonography of lower limbs, if necessary 4. Those with severe diseases (cardiac disorders or renal insufficiency) such that the ambulatory evaluation is not attainable 5. Those with other specific spinal diseases (ankylosing spondylitis, spinal osteomyelitis, metabolic diseases, severe osteoporosis, etc.) 6. Those with severe neurological defects including foot drop or cauda equina syndrome 7. Those with spinal instability confirmed by L-spine x-ray flexion and extension views. Spinal instability will be defined as observing one or more of the following: 4.5 mm sagittal plane translation, 20 degrees of sagittal plane rotation at L4-5, or 25 degrees of sagittal plane rotation at L5-S1. 8. Those with malignancy 9. Those with psychiatric conditions such as major depressive disorder and anxiety disorder in the past or present (e.g., panic disorder, episodes of mania, delusion, and schizophrenia) 10. Those using narcotic analgesics, including the external dosage form or patch 11. Those on medications for respiratory diseases including gastritis, stomach ulcer, and irritable bowel syndrome 12. Pregnant women, lactating women, or those planning to become pregnant 13. Those who appear likely to encounter difficulties in adhering to this protocol such as those regarding treatment, hospitalization, or preparation for the survey 14. Those subjects who the clinical investigators judge to be inappropriate |
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Mokhuri Oriental Medicine Hospital | Seoul | |
| United States | Mayo Clinic | Rochester | Minnesota |
| Lead Sponsor | Collaborator |
|---|---|
| Kim Ki Ok | Korea Health Industry Development Institute, Kyunghee University Medical Center, Mayo Clinic |
United States, Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | 0 to 100 Visual Analogue Scale (VAS) for low back pain | The degree of pain recognized as backache is indicated on a 100 mm straight line. The participant is to indicate the average level of lumbar pain experienced for the past one week. | 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 18th, 30th, 54th and 102th weeks | |
| Secondary | 0 to 100 Visual Analogue Scale (VAS) for leg pain | The degree of pain recognized as leg pain is indicated on a 100 mm straight line. The participant is to indicate the average level of lumbar pain experienced for the past one week. | 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 18th, 30th, 54th and 102th weeks | |
| Secondary | EQ-5D | For assessing quality of life, participants must place checkmarks at the most appropriate points in response to inquiries on each of the five items regarding their health conditions. | 2nd, 3rd, 4th, 5th, 6th, 7th, 18th, 30th, 54th and 102th weeks | |
| Secondary | Oswestry Disability Index | ODI is the index derived from the Oswestry disability questionnaire (ODQ) for assessing the degree of pain, sleep disturbance, self-treatment, walking, sitting, standing, moving, sexual life, social activities, and travel. | 2nd, 3rd, 4th, 5th, 6th, 7th, 18th, 30th, 54th and 102th weeks | |
| Secondary | Roland-Morris Disability Questionnaire (RMDQ) | The Roland-Morris Disability Questionnaire (RMDQ) is a tool that is widely used for evaluating the functional conditions of patients with low back pain. | 2nd, 6th, 7th, 18th, 30th, 54th and 102th weeks | |
| Secondary | Zurich Claudication Questionnaire (ZCQ) | Zurich Claudication Questionnaire (ZCQ) is an instrument for assessing pain and symptoms related to the spinal stenosis. | 2nd, 6th, 7th, 18th, 30th, 54th and 102th weeks | |
| Secondary | Walking duration and distance free of leg pain | Patients walk on the revolving tracks to a distance of 25m at their preferred speed. | 2nd, 3rd, 4th, 5th, 6th, 7th, 18th, 30th, 54th and 102th weeks | |
| Secondary | The ratio between the actual duration of participation and the originally scheduled duration in each group | Participants whose 0 to 100 VAS for back pain and leg pain would decrease below 10 at every-week evaluation will stop the treatment immediately. The numbers of patients who stop the scheduled treatments early and finished full scheduled treatments will be assessed in each group and the differences in the ratio between groups will be assessed. | 7th week | |
| Secondary | Treadmill test | The patients shall walk on the level treadmill at a speed of 1.5 miles (2.414 km/sec). The time until they feel pain in their legs is to be measured. | 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 18th, 30th, 54th and 102th weeks | |
| Secondary | Adverse event assessments | . Participants voluntarily report adverse events and experiments are needed to observe them on a regular basis. | 2nd, 3rd, 4th, 5th, 6th, 7th, 18th, 30th, 54th and 102th weeks | |
| Secondary | Investigation for the presence of any additional spondylolisthesis treatment and the types thereof | Concomitant medication or treatments will be recorded during the follow up period. | 18th, 30th, 54th and 102th weeks |